Thomas E. Reynolds v. Behrman Capital IV L.P.

988 F.3d 1314
CourtCourt of Appeals for the Eleventh Circuit
DecidedFebruary 23, 2021
Docket19-13537
StatusPublished
Cited by21 cases

This text of 988 F.3d 1314 (Thomas E. Reynolds v. Behrman Capital IV L.P.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Thomas E. Reynolds v. Behrman Capital IV L.P., 988 F.3d 1314 (11th Cir. 2021).

Opinion

USCA11 Case: 19-13537 Date Filed: 02/23/2021 Page: 1 of 23

[PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT ________________________

No. 19-13537 ________________________

D.C. Docket No. 2:18-cv-00514-ACA

THOMAS E. REYNOLDS,

Plaintiff - Appellant,

versus

BEHRMAN CAPITAL IV L.P., AXA PRIMARY FUND AMERICA IV LP, AXA PRIVATE CAPITAL I, LP, CORE AMERICAS/GLOBAL HOLDINGS, LP, GLOBAL FUND PARTNERS II, LP, et al.,

Defendants - Appellees,

BEHRMAN BROTHERS MANAGEMENT CORPORATION, et al.,

Defendants.

________________________

Appeal from the United States District Court for the Northern District of Alabama ________________________

(February 23, 2021) USCA11 Case: 19-13537 Date Filed: 02/23/2021 Page: 2 of 23

Before JORDAN, LAGOA, and BRASHER, Circuit Judges.

JORDAN, Circuit Judge:

Thomas Reynolds, the Chapter 7 trustee for the bankruptcy estates of

Atherotech Inc. and Atherotech Holdings, appeals the dismissal of his complaint for

lack of personal jurisdiction. The district court, following removal of the case from

Alabama state court, applied the doctrine of derivative jurisdiction articulated in

Lambert Run Coal Co. v. Baltimore & O.R. Co., 258 U.S. 377, 382 (1922), and ruled

that because the state court did not have personal jurisdiction over the defendants

under Alabama’s long-arm statute, it too lacked personal jurisdiction. In so ruling,

the district court concluded that Mr. Reynolds could not rely on Bankruptcy Rule

7004(d) (which looks to a defendant’s national contacts and permits nationwide

service of process) to establish personal jurisdiction. And it denied as futile Mr.

Reynolds’ motion to transfer the case to the Southern District of New York under

28 U.S.C. § 1406, explaining that under the doctrine of derivative jurisdiction a New

York district court would likewise lack personal jurisdiction over the defendants.

The Supreme Court has applied the doctrine of derivative jurisdiction only

with respect to subject-matter jurisdiction, so that if a state court lacks subject-matter

jurisdiction over a case when it is initially filed, a federal court also lacks subject-

matter jurisdiction when the case is removed (even if the federal court would have

had jurisdiction had the case originally been filed in a federal forum). The main

2 USCA11 Case: 19-13537 Date Filed: 02/23/2021 Page: 3 of 23

question for us in this appeal is whether the doctrine applies when the state court

from which the case is removed lacks personal jurisdiction over the defendants.

I

We accept as true, at this stage of the litigation, the facts as alleged in the

complaint filed by Mr. Reynolds in Alabama state court (and later amended in

federal court). See Louis Vuitton Malletier, S.A. v. Mosseri, 736 F.3d 1339, 130

(11th Cir. 2013). Given the posture of the appeal, we express no view on the validity

of the allegations or the merits of the claims.

A

Atherotech operated a laboratory that conducted testing on blood cholesterol

levels. Atherotech was wholly owned by Atherotech Holdings, which was in turn

owned by three shareholders: Behrman Capital IV LP, Behrman Brothers LLC, and

Midcap Financial Investment, LP. Behrman Capital was the majority shareholder

of Atherotech Holdings, owning 94% of its stock and controlling three of five seats

on its board of directors. Behrman Brothers—which was also Behrman Capital’s

general partner—and MidCap owned the remaining shares in Atherotech Holdings.

As part of its business, Atherotech paid physicians who ordered blood

cholesterol levels a processing and handling fee, known as a P&H fee. Although

Medicare rules and regulations prohibit the payment of P&H fees, Atherotech

3 USCA11 Case: 19-13537 Date Filed: 02/23/2021 Page: 4 of 23

nevertheless submitted claims for those fees to Medicare and other federal healthcare

programs.

In 2012, the Department of Justice began to investigate Atherotech’s

payments of P&H fees as a potential violation of the False Claims Act, 31 U.S.C. §§

3729–3730, and the Anti-Kickback Statute, 42 U.S.C. § 1320a-7b. Violations of the

False Claims Act can result in a per-claim penalty of between $5,500 and $11,000,

in addition to treble damages. See 31 U.S.C. § 3729(a).

Despite knowing of the investigation, Atherotech continued to make P&H fee

payments and submit Medicare claims for those payments. From January of 2011

through June of 2013, Medicare reimbursed Atherotech about $35,691,000 for tests

associated with P&H fee payments. The complaint alleges that, by June of 2013,

Atherotech had up to $107,073,000 in contingent liabilities for violations of the False

Claims Act.

In 2013, as the DOJ investigation was ongoing, Atherotech borrowed $40.5

million under a credit agreement. Atherotech then executed a dividend

recapitalization under which it paid Atherotech Holdings’ shareholders—Behrman

Capital, Behrman Brothers, and MidCap—dividends totaling $31,872,860.75.

Behrman Capital received $31,433,596.05; Behrman Brothers received $87,374.00;

and MidCap received $351,890.70. Behrman Capital distributed its portion of the

dividend to its limited partners and its general partner, Behrman Brothers. Behrman

4 USCA11 Case: 19-13537 Date Filed: 02/23/2021 Page: 5 of 23

Brothers in turn distributed its share of the dividends to its members, along with the

portion it received from Behrman Capital as its general partner.

By July of 2014, Atherotech could no longer pay P&H fees, and its revenues

decreased significantly. From July through October of 2015, Behrman Capital

invested $6.9 million in Atherotech to keep the business afloat. Despite the influx

of funds, Atherotech and Atherotech Holdings filed for bankruptcy in March of

2016. The bankruptcy court appointed Mr. Reynolds as the Chapter 7 trustee for

both companies, and he eventually sold Atherotech’s assets for $19.6 million.

B

In March of 2018, Mr. Reynolds, as trustee for the bankruptcy estates of

Atherotech and Atherotech Holdings, filed a complaint in Alabama state court. The

initial complaint named 30 defendants: Behrman Capital; Behrman Capital’s 15

limited partners; Behrman Brothers; Behrman Brothers’ 12 members; and MidCap.

Mr. Reynolds asserted several federal and state law claims stemming from the

dividend issued by Atherotech Holdings to its shareholders.

The defendants removed the case to the district court under 28 U.S.C. § 1441,

asserting that the complaint implicated significant federal issues, and alternatively

under 28 U.S.C. § 1452(a), asserting that pursuant to 28 U.S.C. § 1334 the district

court had subject-matter jurisdiction under the Bankruptcy Code. The district court

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
988 F.3d 1314, Counsel Stack Legal Research, https://law.counselstack.com/opinion/thomas-e-reynolds-v-behrman-capital-iv-lp-ca11-2021.